Abstract
[Background] A part of asthma patients does not respond well to inhaled corticosteroids (ICS) and the benefit by high-dose ICS is limited in such patients. The aim of this study is to establish the clinical or genetic factor for predicting the response to ICS treatment.
[Method] Patients treated only by ICS for more than 6 months were enrolled and classified into responder group (R group, n=30) if FEV1 improvement ≥ 5% and nonresponder group (NR group, n =40, FEV1 improvement<5%). The relationship between ICS response and pretreatment clinical indices and 21 single nucleotide polymorphism (SNP) were retrospectively analyzed.
[Results] In R group, peripheral blood eosinophil% (R: NR = 7.5: 4.3%) and serum total IgE level (550.4: 497.1 U/ml) was significantly higher as compared to NR group. R group also showed significantly lower %VC (97.5: 114.8%), %FEV1.0 (77.9: 101.3%), FEV1.0% (67.5:76.4%) and higher bronchial hyperresponsiveness. Bronchial reversibility test was available in 30 patients (R: n=11, NR: n=19) and reversibility was significantly higher in R group (15.9: 5.4%). By logistic multivariate analysis for those 30 patients, bronchial reversibility was significantly related to ICS response. SNP in IFNγR1 L467P was also related to ICS response. Post /Pre FEV1 ratio was significantly higher in homo/hetero group as compared to wild group (140.2 vs 108.8%).
[Conclusion] Pretreatment bronchial reversibility was identified as a prediction factor for ICS response. It has been reported that SNP in IFNγR1 is associated with allergic diseases and serum IgE level and the SNP might be potentially related to ICS response.
- © 2014 ERS
